Radcliffe Capital Management’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-143,911
Closed -$16.5K – 510
2026
Q2
$16.5K Sell
143,911
-87,640
-38% -$9.05K ﹤0.01% 428
2026
Q1
$13.3K Sell
231,551
-93,549
-29% -$9.9K ﹤0.01% 391
2025
Q4
$56.5K Hold
325,100
– – ﹤0.01% 265
2025
Q3
$3.34M Buy
+325,100
New +$60.4K 0.21% 110

Other funds holding DMAAR

Radcliffe Capital Management's DMAAR Position: Q3 2026 in Review

Radcliffe Capital Management sold out of Drugs Made In America Acquisition Corp Rights (DMAAR) in Q3 2026, closing a stake of 143,911 shares — an estimated $16.5K sold.

Radcliffe Capital Management first reported a position in DMAAR in Q3 2025 and held it in 4 quarters. The position peaked at $3.34M in Q3 2025. 32 funds tracked by Wall St. Rank hold DMAAR as of Q3 2026.

  • Radcliffe Capital Management reported no remaining Drugs Made In America Acquisition Corp Rights position as of Q3 2026 after selling out during the quarter.
  • Radcliffe Capital Management sold 143,911 Drugs Made In America Acquisition Corp Rights shares in Q3 2026, an estimated $16.5K.
  • Radcliffe Capital Management first reported a position in Drugs Made In America Acquisition Corp Rights in Q3 2025 and held it in 4 quarters.
  • Radcliffe Capital Management's Drugs Made In America Acquisition Corp Rights position peaked at $3.34M in Q3 2025.
  • 32 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q3 2026.

Based on Radcliffe Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.